Sun Pharma arm gets USFDA nod for Elepsia XR, an antiepileptic drug
The United States Food and Drug Administration (USFDA) has granted approval for the New Drug Application to a wholly-owned subsidiary of Sun Pharma for Elepsia XR in the strengths of 1,000 mg and 1,500 mg, the company said in a regulatory filing.
Elepsia XR is a prescription medication used to treats partial onset seizures. Elepsia XR belongs to a group of drugs called anticonvulsants, which may work by decreasing abnormal excitement in the brain. This medication comes as an extended-release tablet and is usually taken once a day.
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd